John C. Murray - Concepedia

Author

John C. Murray

Also Known As

J C Murray, J. C. F. MURRAY, J. Murray, J.C. Murray, J.Charles F. Murray, JOHN C. F. MURRAY, John C Murray, John C. F. Murray, John C. Murray, John Murray

Publications

937

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of Cambridge Délégation Paris 7 Centre National de la Recherche Scientifique Institut Pasteur

About

John C. Murray is an author at Pfizer (United States) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	427
2	Natural Sciences	8	8	314
3	Engineering	2	2	80
4	Health Sciences	1	1	41
5	Public Health	1	1	42

John C. Murray

Publications

850

Citations

H-Index

Page 1

	Year	Citations
IN VITRO METABOLISM STUDIES ON THE ISOXAZOLE RING SCISSION IN THE ANTI-INFLAMMATORY AGENT LEFLUNOMIDE TO ITS ACTIVE α-CYANOENOL METABOLITE A771726: MECHANISTIC SIMILARITIES WITH THE CYTOCHROME P450-CATALYZED DEHYDRATION OF ALDOXIMES Amit S. Kalgutkar, Nguyen Thi Thu Hang, Alfin D. N. Vaz, Drug Metabolism and Disposition	2003	114
<i>In Vitro</i> and <i>In Vivo</i> Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection Thomas Colley, Alexandre Alanio, Steven L. Kelly, Antimicrobial Agents and Chemotherapy	2017	82
Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors Michael A. Brodney, Elizabeth M. Beck, Christopher R. Butler, Journal of Medicinal Chemistry Reduce RiskDrug TargetPeptide SciencePharmacotherapyDrug–drug Interactions	2015	78
Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent Lindsey Cass, Alison D. Murray, Amanda Davis, Pharmacology Research & Perspectives	2020	63
Spirocyclic Sulfamides as β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer’s Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies To Identify Centrally Efficacious Inhibitors Michael A. Brodney, Gabriela Barreiro, Kevin Ogilvie, Journal of Medicinal Chemistry Drug TargetPeptide SciencePharmacotherapyPharmaceutical ChemistryMolecular Pharmacology	2012	60
Telescoped Flow Process for the Syntheses of <i>N</i>-Aryl Pyrazoles Bryan Li, Daniel W. Widlicka, Steven J. Boucher, Organic Process Research & Development N-aryl PyrazoleChemical EngineeringEngineeringN-aryl PyrazolesOrganic Chemistry	2012	58
Evidence for the role of vitamin B-6 as a cofactor of lysyl oxidase John C. Murray, C. I. Levene Biochemical Journal Bioorganic ChemistryLipid PeroxidationRedox BiologyOxidative StressLysyl Oxidase	1977	49
Discovery of a Series of Efficient, Centrally Efficacious BACE1 Inhibitors through Structure-Based Drug Design Christopher R. Butler, Michael A. Brodney, Elizabeth Beck, Journal of Medicinal Chemistry Drug TargetBrain AvailabilityPeptide ScienceChemical BiologyMolecular Pharmacology	2015	45
THE ÆTIOLOGICAL ROLE OF MATERNAL VITAMIN-B6 DEFICIENCY IN THE DEVELOPMENT OF ATHEROSCLEROSIS C. I. Levene, John C. Murray The Lancet Metabolic SyndromeVascular DiseaseCardiovascular DiseaseGynecologyMaternal Health	1977	42
The effect of pyridoxine deficiency on lysyl oxidase activity in the chick John C. Murray, David R. Fraser, C. I. Levene Experimental and Molecular Pathology Animal PhysiologyBiochemistryLysyl Oxidase ActivityMedicineLipid Peroxidation	1978	41

Page 1